{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 76 of 122', 'Table 19: Evaluation of Asthma Based on NHLBI Criteria', 'Intermittent', 'Persistent: Mild', 'Persistent: Moderate', 'Persistent: Severe', 'Classification', '(Step 1)', '(Step 2)', '(Step 3 or 4)', '(Step 5 or 6)', 'Symptoms', '<2 days/week', '> 2 days/week but not daily', 'Daily', 'Throughout the day', 'Night-time awakenings', 'Subject aged 0-4 years', '0', '1-2 times/month', '3-4 times/month', '> 1 time/week', 'Subject aged > 5 years', '<: 2 times/month', '3-4 times/month', '> 1 time/week but not nightly', 'Often 7 times/week', 'Short-acting inhaled', '<2 days/week', '> 2 days/week, but not daily', 'Daily', 'Several times per day', 'beta2-agonist use', '(and not more than once a day', 'for subject 12 years)', 'Interference with normal', 'None', 'Minor limitation', 'Some limitation', 'Extremely limited', 'activity', 'Lung function', 'Subject aged 0-4 years', 'Not applicable', 'Not applicable', 'Not applicable', 'Not applicable', 'Subject aged 5-11 years', 'Normal FEV1 between', 'FEV1 80% predicted', 'FEV1 > 60% but < 80%', 'FEV1 < 60% predicted', 'exacerbations', 'FEV1/FVC > 80% and VI 85%', 'predicted', 'FEV1/FVC < 75%', 'FEV1 > 80% predicted', 'FEV1/FVC > 75% and VI 80%', 'FEV1/FVC > 85%', 'Subject aged > 12 years', 'Normal FEV1 between', 'FEV1 > 80% predicted', 'FEV1 > 60% but < 80%', 'FEV1 < 60% predicted', 'exacerbations', 'FEV1/FVC normal [1]', 'predicted', 'FEV1/FVC reduced > 5% [1]', 'FEV1 > 80% predicted', 'FEV1/FVC reduced VI 5% [1]', 'FEV1/FVC normal [1]', 'Adapted from NHLBI, 2007.', '[1] Normal FEV1/FVC by age: 8-19 years, 85%; 20-39 years, 80%; 40-59 years, 75%; 60-80 years, 70%.', 'FEV1, forced expiratory volume in the first second of expiration; FVC, forced vital capacity.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 77 of 122', '9.3.2', 'TNSS Questionnaires', 'The Total Nasal Symptom Score (TNSS) is used to assess the severity of allergic rhinitis and', 'will be administered only to subjects with pre-existing allergic rhinitis. The TNSS (short', 'form) consists of 3 questions that address nasal obstruction, rhinorrhea, and nasal', 'itch/sneezing (Downie, 2004). Each question has a choice of 4 responses that range from', '0 (no symptoms) to 3 (severe symptoms). The subject is asked to recall symptoms over the', 'last week to allow calculation of the symptom score.', '9.3.3', 'SCORAD Index', 'The scoring atopic dermatitis (SCORAD) index is used to assess the severity of atopic', 'dermatitis and will be administered only to subjects with pre-existing atopic dermatitis', '(European Task Force on Atopic Dermatitis, 1993). The SCORAD index is based on the', 'combination of the following:', 'Extent of lesions (accounts for about 20% of the total score).', 'Intensity, based on 6 items (erythema, edema/papulation, oozing/crusts, excoriations,', 'lichenification, and dryness), each graded from 0 (absent) to 3 (severe) according to', 'reference photographs (accounts for about 60% of the total score).', 'Subjective items (pruritus and sleep loss). The subject (aged >7 years) or', 'parent/caregiver will indicate the average value for pruritus and sleep loss on a visual', 'analog scale (accounts for about 20% of the total score).', '9.3.4', 'PEESS v2.0 Questionnaire', 'The PEESS v2.0 (Martin, 2015; Franciosi, 2011) is used to assess the frequency and severity', 'of EoE symptoms in the last month and will be administered only for subjects with GI', 'adverse events of interest (Section 5.5.1, Section 8.5.6.2). The PEESS v2.0 consists of', '4 domains (dysphagia, GERD, nausea/vomiting, and pain) and 20 items. Each item contains', 'response options from 0 to 4. A higher total or domain score indicates more frequent and/or', 'severe symptoms. The parent/caregiver completes the Parent Report and subjects aged', '> 8 years complete the Children and Teens Report.', 'The PEESS v2.0 was not designed to establish a diagnosis of EoE; the use of this', 'questionnaire to monitor the clinical course of GI symptoms must be considered exploratory.', 'However, the PEESS v2.0 has shown content and construct validity (Martin, 2015;', 'Franciosi, 2011) and is a promising tool for following the clinical course of EoE or an', 'EoE-like immune-mediated GI syndrome. The questionnaire has the potential to reveal', 'trends toward symptomatic improvement or worsening that may otherwise go undetected.', '9.3.5', 'Physical Examinations and Vital Signs', 'The investigator will perform physical examinations according to the schedule of activities.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 78 of 122', 'Physical examinations will include an age-appropriate assessment of systems (eg, general', 'appearance, head, eyes, ears, nose, mouth, skin, heart, lungs, lymph nodes, GI, genitourinary,', 'neurologic, and skeletal) per standard of care at the study site or as clinically indicated by', 'symptoms. Symptom-directed physical examinations will concentrate on typical target organ', 'areas for an allergic response, including the skin, oropharynx, and upper and lower', 'respiratory, GI, and cardiovascular systems.', 'Vital sign measurements will include blood pressure, heart rate, and temperature.', 'Weight and height will be measured at specific visits according to the schedule of activities.', '10 STATISTICAL METHODS', '10.1 Statistical and Analytical Plans', 'The statistical methods and data presentations for reporting the study results will be', 'described in detail in the statistical analysis plan.', 'Randomization will be central and treatment allocation will be 2:1 (AR101 treatment or', 'standard of care alone). Randomization will be stratified by age group (4-12 years and', '13-17 years).', 'Data for demographic and baseline characteristics, HRQOL scores, efficacy, and safety will', 'be summarized by treatment group (AR10 treatment VS standard of care alone). Summary', 'statistics will include the mean, number of observations, standard deviation, median,', 'minimum and maximum values for continuous variables, and frequencies and percentages for', 'categorical variables.', 'Statistical significance is defined as p < 0.05 and tests will be 2-sided, unless otherwise', 'specified. CIs will be calculated at the 95% level, reflecting a type I error rate of 0.05.', 'Missing values for efficacy variables will not be replaced or imputed; no interpolation or', 'extrapolation will be applied to missing values.', '10.2 Analysis Populations', 'The ITT population (ie, full analysis set) will be defined as all subjects who receive any part', 'of 1 dose of study product and complete 1 study visit if assigned to AR101 treatment, or who', 'complete 1 study visit after the screening visit if assigned to standard of care alone. The ITT', 'population will be used for all HRQOL and efficacy analyses unless otherwise specified, and', 'analyzed according to randomized treatment. If no subjects receive the incorrect treatment,', 'the ITT population will be the same as the safety population.', 'The AR101 completer population will be defined as all AR101-treated subjects in the ITT', 'population who complete the exit visit (ie, do not discontinue early). The standard of care', 'completer population will be defined as all subjects in the ITT population receiving standard']", "completion": ""}